SOCS3 and neoplasm: In the case of SOCS3, there was a significantly higher immunoexpression level in cancer in comparison to the control (mastopathy vs. tumor: 6.46 ± 2.42 vs. 7.77 ± 2.77, p < 0.001) (Figure 2C).